3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
5
von Hippel-Lindau Disease
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Hemangioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Interventions
lutetium Lu 177 dotatate
4
3-Iodobenzylguanidine
4
anlotinib
3
gallium Ga 68 dotatate
2
cabozantinib
2
Temozolomide
2
Sunitinib
2
Phenoxybenzamine
2
Magnetic Resonance Spectroscopy
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
vandetanib
1
pembrolizumab
1
olaparib
1
lanreotide
1
fluorodopa F 18
1
fludarabine phosphate
1
belzutifan
1
atezolizumab
1
Vorinostat
1
Specimen Handling
1
Radiosurgery
1
Interleukin-13
1
Genetic Testing
1
Fluorodeoxyglucose F18
1
Everolimus
1
Erlotinib Hydrochloride
1
Doxazosin
1
Cyclophosphamide
1
Blood Specimen Collection
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Paraganglioma
×
belzutifan
×
Clear all
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled